Has synthetic chemical screening hit the wall?

Traditional pharma libraries often yield hit rates below 0.1% when searching for complex aging targets. It’s a massive needle-in-a-haystack problem that costs millions and takes years. Even then, once de-risked preclinical, it takes 40 programs to get an approval. Microbiome-based starting point, once de-risked, takes only 4.4 programs for approval.

The Microbial World Crushes the Purely Synthetic Approach with or without AI

We look where evolution has already done the heavy lifting: the unculturable microbiome.

We recently completed a massive computational screening campaign of 73,500 entirely novel, BUT NATURE MADE, dark-matter microbiome molecules against a premium panel of human longevity and cellular stress targets.

The data speaks for itself:

Total Novel Molecules Screened: 73,500
Targeted Longevity Actives Identified: 889
Platform Hit Rate: ~1.2% (The ultimate sweet spot for specific, pocket-driven binding)
High-Confidence Leads: 255 pristine, unmined molecular assets

Where are these novel molecules clustering? The structural data heavily map to the core pillars of systemic aging:

1️⃣ KEAP1/NRF2 Axis (625 compounds): Natural master regulators of cellular antioxidant defense.
2️⃣ Class I HDACs & SIRT1 (Over 900 combined hits): Highly precise epigenetic modifiers.
3️⃣ NLRP3 Inflammasome (140 compounds): Novel scaffolds evolved to naturally dampen host “inflammaging."

By screening molecules that co-evolved with biology over millennia, we aren’t guessing at shapes—we are uncovering a pre-optimized therapeutic goldmine.

The next phase? Isolating the elite 255 high-confidence hits for structural elucidation and in vitro validation.

💡 Want a look at the methodology behind the screen? Drop a comment below with “METRICS" and I’ll DM you an anonymized summary of our platform’s screening architecture.

Also, take a look at our pipeline page for molecules or IP ready for wet-lab screening https://biosortia.com/therapeutic-pipeline.php